HIF1A and breast carcinoma: However, this is not supported by our observation in human breast cancer cells in vitro and in vivo studies on nude mice, which showed that the expression of HIF-1α in the residual tumors is enhanced not only in poor-responders to primary endocrine therapy, but also in good-responders.